Concepedia

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

Ying Chen, Brian I. Rini, Robert J. Motzer, Janice P. Dutcher, Olivier Rixe, George Wilding, Walter M. Stadler, Jamal Tarazi, May Garrett, Yazdi K. Pithavala

Targeted Oncology · 2015 · 20 citations · 18 references

DOI

Concepts

References

18

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak et al. · The Lancet · 2011 · 1.8K citations

, , +8

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

, , +17

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

Radojka M. Savić, Mats O. Karlsson · The AAPS Journal · 2009 · 614 citations · Full text

, , +11

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Hope S. Rugo, Roy S. Herbst, Glenn Liu et al. · Journal of Clinical Oncology · 2005 · 485 citations · Full text

, , +17

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson et al. · The Lancet Oncology · 2007 · 436 citations

, , +14